ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Application Value of STOP-Bang Questionnaire in Predicting Abnormal Metabolites.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the application value of STOP-Bang questionnaire (SBQ) in predicting abnormal metabolites. Methods: Totally 121 patients were included into the study and filled the questionnaires, and their clinical data were collected at the same time. These patients were grouped according to the questionnaire scores. The clinical data of patients in various groups were compared using R4.3.1 statistical software. Results: Based on the SBQ score, the patients were divided into the following groups: low-risk group (0-2 scores), mid-risk group (3-4 scores), and high-risk group (5-8 scores). SBQ score was related to several abnormal metabolites. A higher SBQ score indicated elevated uric acid (UA), waist circumference (WC), fasting blood glucose (FBG), hemoglobin A1c (HbA1c) and triacylglycerol (TG), but notably lower high density lipoprotein-cholesterol (HDL-C). In respect of liver function, alanine aminotransferase (ALT) and aspartate transaminase (AST) were both in low/mid-risk group than in high-risk group. With respect to renal function, there was a statistically significant difference in serum creatinine (SCr) (lowest in the low-risk group and highest in the high-risk group) but no such difference in estimated glomerular filtration rate (eGFR) among the three groups. The diagnosability analysis showed that the AUROC proved the good performance of SBQ in predicting metabolic syndrome (MetS) and hyperuricemia (HUA). Conclusion: OSA frequently co-occurs with various metabolic disorders. SBQ, a widely used tool for assessing the risk of OSA, may also be a potential tool for predicting the presence of metabolic diseases. A higher SBQ score indicates a heightened susceptibility to more abnormal metabolites, but SBQ is poor in predicting liver and renal functions. The patients with SBQ score ≥3 are suggested to pay a visit to the Endocrine Department and Sleep Disorders Center for a comprehensive evaluation of comorbid Obstructive sleep apnea (OSA) and the management of systematic metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.